Receptor‐mediated drug delivery presents an opportunity to enhance therapeutic efficiency
by accumulating drug within the tissue of interest and reducing undesired, off‐target effects …

Benign prostatic hyperplasia (BPH) is a benign enlargement of the prostate in which
incidence increases linearly with age, beginning at about 50 years old. BPH is a significant …

Background The androgen receptor (AR) is a pivotal drug target for the treatment of prostate
cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR …

The androgen receptor (AR) plays a predominant role in prostate cancer (PCa) pathology. It
consists of an N-terminal domain (NTD), a DNA-binding domain (DBD), a hinge region (HR) …

The androgen receptor (AR) is a transcription factor that has a pivotal role in the occurrence
and progression of prostate cancer. The AR is activated by androgens that bind to its ligand …

Androgen receptor (AR) is closely associated with a group of hormone‐related diseases
including the cancers of prostate, breast, ovary, pancreas, etc and anabolic deficiencies …

Prostate cancer (PCa), a hormonally-driven cancer, ranks first in incidence and second in
cancer related mortality in men in most Western industrialized countries. Androgen and …

Common uterine diseases include endometriosis, uterine fibroids, endometrial polyps,
endometrial hyperplasia, endometrial cancer, and endometrial dysfunction causing infertility …

Prostate cancer (PCa) is a leading cause of death for men in North America. The androgen
receptor (AR)-a hormone inducible transcription factor-drives expression of tumor promoting …

Prostate cancer (PCa) is the second most common cause of cancer‐related mortality in men
in the United States. The androgen receptor (AR) and the physiological pathways it …